Objectivity and equity: clarity required. A response to Hill and Olson

Pharmacoeconomics. 2014 Dec;32(12):1249-50. doi: 10.1007/s40273-014-0239-6.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cost-Benefit Analysis / methods*
  • Humans
  • Social Values*
  • Technology Assessment, Biomedical / methods*